Physician profile
Emily Arndt Yoder
NPI 1164106084
$2,634.54
in general payments reported to CMS, 2019-2025
23 companies · $1,861 in 2025
The $1,861 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $147 · 2024: $627 · 2025: $1,861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,634.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $514.64 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $462.07 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $337.75 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $197.27 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $150.57 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $116.15 | 2024-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.11 | 2023-2025 | Jardiance |
| Exact Sciences Corporation | $92.84 | 2023-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $77.93 | 2023-2025 | Zoryve, Livalo, Seglentis |
| Bayer Healthcare Pharmaceuticals INC. | $75.66 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.39 | 2024-2025 | Xifaxan, Trulance |
| Amgen INC. | $66.54 | 2024-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $59.65 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $54.38 | 2025 | Trintellix |
| Pfizer INC. | $53.47 | 2023-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $45.31 | 2024-2025 | Ibsrela |
| Axsome Therapeutics, INC. | $32.10 | 2025 | Auvelity |
| Currax Pharmaceuticals LLC | $31.78 | 2025 | Contrave, Onzetra Xsail |
| Gilead Sciences, INC. | $21.86 | 2024 | |
| Astellas Pharma US INC | $19.31 | 2025 | Veozah |
| Lundbeck LLC | $18.34 | 2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $14.92 | 2023 | Gvoke Hypopen |
| Abbott Laboratories | $14.50 | 2024 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Yoder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.